Literature DB >> 22399204

Women have better long-term prognosis than men after cardiac resynchronization therapy.

Stanislava Zabarovskaja1, Fredrik Gadler, Frieder Braunschweig, Marcus Ståhlberg, Jonas Hörnsten, Cecilia Linde, Lars H Lund.   

Abstract

AIMS: Cardiac resynchronization therapy (CRT) improves prognosis in patients with moderate-to-severe heart failure, reduced left ventricular ejection fraction, and wide QRS complexes. However, CRT may be under-utilized in women and data on long-term follow-up are still scarce. The aim was to investigate long-term mortality and hospitalization and prognostic impact of gender after CRT. METHODS AND
RESULTS: Data on 619 consecutive patients (19% women) that received CRT at a single centre between 1998 and 2008 were collected from electronic medical records and national death and hospitalization registries up to 2010. The primary endpoint was death of any cause and the secondary endpoint was combined death of any cause or heart failure hospitalization. Over a mean follow-up of 1320 ± 786 days, 215 (35%) patients reached the primary endpoint and 437 (71%) the secondary endpoint. Overall, 1-, 5-, and 10-year survivals were 91, 63, and 39%, respectively. Female gender was the only independent predictor of all-cause mortality; hazard ratio (HR) 0.44 [95% confidence interval (CI), 0.21-0.90; P= 0.025]. Women also had a trend towards lower risk for the secondary endpoint, HR 0.68 (95% CI, 0.45-1.04; P= 0.072).
CONCLUSION: In this registry analysis, patients with CRT had similarly high short-term survival to those in controlled trials, and this favourable prognosis was sustained over the long term.Women had lower all-cause mortality than men.

Entities:  

Mesh:

Year:  2012        PMID: 22399204     DOI: 10.1093/europace/eus039

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  17 in total

Review 1.  ICD and CRT use in ischemic heart disease in women.

Authors:  Nishaki Kiran Mehta; William T Abraham; Melanie Maytin
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

Review 2.  Sex differences in device therapy for heart failure: utilization, outcomes, and adverse events.

Authors:  Naomi D Herz; Joseph Engeda; Robbert Zusterzeel; William E Sanders; Kathryn M O'Callaghan; David G Strauss; Samantha B Jacobs; Kimberly A Selzman; Ileana L Piña; Daniel A Caños
Journal:  J Womens Health (Larchmt)       Date:  2015-03-20       Impact factor: 2.681

Review 3.  Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease.

Authors:  Ronée E Harvey; Kirsten E Coffman; Virginia M Miller
Journal:  Womens Health (Lond)       Date:  2015-03

Review 4.  Gender Disparities Across the Spectrum of Advanced Cardiac Therapies: Real or Imagined?

Authors:  Roberta C Bogaev
Journal:  Curr Cardiol Rep       Date:  2016-11       Impact factor: 2.931

5.  Clinical outcome after 1 year of cardiac resynchronisation therapy: national results from the European CRT survey.

Authors:  Wolfgang Dichtl; Bernhard Strohmer; Friedrich Fruhwald
Journal:  Wien Klin Wochenschr       Date:  2013-10-22       Impact factor: 1.704

Review 6.  Future research prioritization in cardiac resynchronization therapy.

Authors:  Marat Fudim; Frederik Dalgaard; Sana M Al-Khatib; Daniel J Friedman; Kathryn Lallinger; William T Abraham; John G F Cleland; Anne B Curtis; Michael R Gold; Valentina Kutyifa; Cecilia Linde; Daniel E Schaber; Anthony Tang; Fatima Ali-Ahmed; Sarah A Goldstein; Brystana Kaufman; Robyn Fortman; J Kelly Davis; Lurdes Y T Inoue; Gillian D Sanders
Journal:  Am Heart J       Date:  2020-02-21       Impact factor: 4.749

Review 7.  An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure.

Authors:  John G Cleland; William T Abraham; Cecilia Linde; Michael R Gold; James B Young; J Claude Daubert; Lou Sherfesee; George A Wells; Anthony S L Tang
Journal:  Eur Heart J       Date:  2013-07-29       Impact factor: 29.983

8.  Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry.

Authors:  Rui Providência; Eloi Marijon; Pier D Lambiase; Abdeslam Bouzeman; Pascal Defaye; Didier Klug; Denis Amet; Marie-Cécile Perier; Daniel Gras; Vincent Algalarrondo; Jean-Claude Deharo; Christophe Leclercq; Laurent Fauchier; Dominique Babuty; Pierre Bordachar; Nicolas Sadoul; Olivier Piot; Serge Boveda
Journal:  J Am Heart Assoc       Date:  2016-02-12       Impact factor: 5.501

9.  Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators.

Authors:  Joachim Seegers; David Conen; Klaus Jung; Leonard Bergau; Marc Dorenkamp; Lars Lüthje; Christian Sohns; Samuel T Sossalla; Thomas H Fischer; Gerd Hasenfuss; Tim Friede; Markus Zabel
Journal:  Europace       Date:  2015-11-29       Impact factor: 5.214

10.  Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure.

Authors:  Crystel M Gijsberts; Lina Benson; Ulf Dahlström; David Sim; Daniel P S Yeo; Hean Yee Ong; Fazlur Jaufeerally; Gerard K T Leong; Lieng H Ling; A Mark Richards; Dominique P V de Kleijn; Lars H Lund; Carolyn S P Lam
Journal:  Heart       Date:  2016-07-11       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.